Koers Diamyd Medical AB (publ) Nasdaq Stockholm
Aandelen
SE0005162880
Biotechnologie & Medisch Onderzoek
Omzet 2024 * | 3 mln. 272K 255K | Omzet 2025 * | 3 mln. 272K 255K | Marktkapitalisatie | 1,1 mld. 99,39 mln. 93,29 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -133 mln. -12,06 mln. -11,32 mln. | Nettowinst (verlies) 2025 * | -165 mln. -14,96 mln. -14,04 mln. | EV/omzet 2024 * | 319 x |
Nettoliquiditeiten 2024 * | 139 mln. 12,61 mln. 11,83 mln. | Nettoliquiditeiten 2025 * | 30 mln. 2,72 mln. 2,55 mln. | EV/omzet 2025 * | 355 x |
K/w-verhouding 2024 * |
-8,03
x | K/w-verhouding 2025 * |
-6,47
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 72,91% |
Recentste transcriptie over Diamyd Medical AB (publ)
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Ulf Hannelius
CEO | Chief Executive Officer | 49 | 10-04-16 |
Founder | 83 | 01-01-96 | |
Anna Styrud
DFI | Director of Finance/CFO | 63 | 01-01-10 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Founder | 83 | 01-01-96 | |
Director/Board Member | 63 | 01-01-12 | |
Director/Board Member | 52 | 28-04-21 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
-3,46% | 102 mld. | |
+1,41% | 96,09 mld. | |
+2,13% | 22,28 mld. | |
-15,84% | 21,4 mld. | |
-9,21% | 18,14 mld. | |
-39,98% | 17,02 mld. | |
-14,65% | 16,09 mld. | |
+4,39% | 13,83 mld. | |
+31,35% | 11,97 mld. |